Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Chemo-radiotherapy in head and neck cancer.
Bourhis J, Guigay J, Temam S, Pignon JP. Bourhis J, et al. Among authors: guigay j. Ann Oncol. 2006 Sep;17 Suppl 10:x39-41. doi: 10.1093/annonc/mdl233. Ann Oncol. 2006. PMID: 17018748 Review. No abstract available.
Advances in nasopharyngeal carcinoma.
Guigay J. Guigay J. Curr Opin Oncol. 2008 May;20(3):264-9. doi: 10.1097/CCO.0b013e3282fad846. Curr Opin Oncol. 2008. PMID: 18391624 Review.
[Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].
Bardet E, Bourhis J, Cals L, Fayette J, Guigay J, Hans S, Saint-Guily JL, Lagarde F, Lallemant B, Milano G, Rolland F, Lefebvre JL. Bardet E, et al. Among authors: guigay j. Bull Cancer. 2009 Oct;96(10):1013-28. doi: 10.1684/bdc.2009.0951. Bull Cancer. 2009. PMID: 19744919 Free article. French.
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Vermorken JB, Guigay J, Mesia R, Trigo JM, Keilholz U, Kerber A, Bethe U, Picard M, Brummendorf TH. Vermorken JB, et al. Among authors: guigay j. Br J Cancer. 2011 May 24;104(11):1691-6. doi: 10.1038/bjc.2011.152. Epub 2011 May 3. Br J Cancer. 2011. PMID: 21540865 Free PMC article. Clinical Trial.
Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).
Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Mignion L, Guigay J, Knoops L, Hamoir M, Machiels JP. Schmitz S, et al. Among authors: guigay j. Ann Oncol. 2012 Aug;23(8):2153-2161. doi: 10.1093/annonc/mdr574. Epub 2012 Jan 10. Ann Oncol. 2012. PMID: 22234739 Free article. Clinical Trial.
166 results